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Abstract
Over 150,000 new people in the United States are diagnosed with colorectal cancer each year. Nearly
a third die from it (American Cancer Society). The only approved noninvasive diagnosis tools currently
involve fecal blood count tests (FOBTs) or stool DNA tests. Fecal blood count tests take only five
minutes and are available over the counter for as low as $15. They are highly specific, yet not nearly as
sensitive, yielding a high percentage (25%) of false negatives (Colon Cancer Alliance). Moreover, FOBT
results are far too generalized, meaning that a positive result could mean much more than just colorectal
cancer, and could just as easily mean hemorrhoids, anal fissure, proctitis, Crohn’s disease, diverticulosis,
ulcerative colitis, rectal ulcer, rectal prolapse, ischemic colitis, angiodysplasia, rectal trauma, proctitis
from radiation therapy, and others. Stool DNA tests, the modern benchmark for CRC screening, have
a much higher sensitivity and specificity, but also cost $600, take two weeks to process, and are not for
high-risk individuals or people with a history of polyps. To yield a cheap and effective CRC screening
alternative, a unique ensemble-based classification algorithm is put in place that considers the FIT re-
sult, BMI, smoking history, and diabetic status of patients. This method is tested under ten-fold cross
validation to have a .95 AUC, 92% specificity, 89% sensitivity, .88 F1, and 90% precision. Once clinically
validated, this test promises to be cheaper, faster, and potentially more accurate when compared to a
stool DNA test.
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1 Overview
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related
deaths in the United States. The American Cancer Society predicts approximately 135,000 new cases
of CRC in 2017 and 50,000 deaths just in the United States. There is a strong inverse association with
CRC screening and CRC incidence and mortality, yet more than one in three eligible Americans are not
up-to-date with the recommended screening (Burke and Mankaney, 2017).
Figure 1: Source: Cancer Treatment Centers of America
2 Problem
Once detected, a colonoscopy can typically remove most polyps or small cancers, but as stated earlier,
screening itself is a major problem. Current noninvasive tests are most commonly fecal occult blood
count tests or stool DNA tests.
Fecal Occult Blood Count Tests
These tests, most commonly seen as guaiac fecal occult blood tests (gFOBT) or fecal immunochemi-
cal tests (FIT) inject biochemicals into the stool to account for occult, or hidden, blood. Occult blood
in the stool is typically a biomarker for bleeding polyps, which very often grow into carcinomas. They
are currently what most doctors use for CRC screening due to their extremely high patient compliance
from their accessibility and ease of use. The test is available over-the-counter, takes five minutes, and
is completely done at home. There is no further work needed once the patient receives his/her results.
Moreover, these tests are highly specific, meaning the people it falsely marks positive is less than 5%. The
problem arises with its use cases. A positive FIT result is simply indicative of abnormal gastrointestinal
activity and not necessarily the presence of CRC. For example, causes of blood in the stool just as easily
indicate the presence of hemorrhoids, anal fissure, proctitis, Crohn’s disease, diverticulosis, ulcerative
colitis, rectal prolapse, ischemic colitis, angiodysplasia, rectal trauma, proctitis from radiation therapy,
and others. Therefore, the FIT is not the most reliable test to screen for just CRC.
Stool DNA Testing
At this time of writing, the only such test is Cologuard, developed by Exact Sciences. This test is
brand new in the market, but it has shown very promising results. This method analyzes the genes
expressed in fecal matter and finds the ones associated with CRC. As a result, its complicated analysis
requires a lab test as opposed to a home test like occult blood testing, which can take up to two weeks to
get a result instead of the five-minute occult blood test. Moreover, the test is not designed for high-risk
individuals, namely people who have had a history of polyps/cancer or for people for whom CRC runs in
the family. On top of that, it comes at a cost upwards of $600, with availability requiring a prescription.
This is quite easily understood because these conditions alter stool DNA that may lead to inaccurate
results. Regardless, its specificity is 89%, while sensitivity is 92% (Colon Cancer Alliance). These results
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are stunning, given the comparison to the occult blood testing. However, the price, accessibility, and
restrictions on who can use it have yielded hesitation in both doctors and patients.
3 Solution
CounteractIO calculates predisposition to CRC through inputs such as age, BMI, diabetes, and smoking
habits. When combined with results of fecal occult blood testing, ensemble learning methods are put
into place in order to boost specificity/sensitivity such that a patient can have the accessibility, ease, and
quickness of an occult blood test with the accuracy of a stool DNA test.
Process
The process is rather straightforward. The patient takes an occult blood test, then opens the Coun-
teractIO app. The app will ask for the patient’s age, BMI, presence of diabetes, and smoking habits
and use these inputs to come up with a probability result of positive or negative for CRC. Since the app
does not collect personal identifying information such as name or even date of birth, it should not be
in violation of any HIPAA regulations. The entirety of the system was developed using data from Dr.
Schloss’ lab at the University of Michigan (Baxter et al., 2016).
Ensemble Learning
The following definitions are used to present the underlying concepts of ensemble methods according
to classic literature (Kuncheva, 2004).
1. Let Ω = {ω1, ω2...ωM} be a set of class labels. Then, a function D : Rn −→ Ω is called a classi-
fier, while a vector #»χ = (χ1 + χ2 + ...χn) ∈ Rn is called a feature vector.
2. Let h1, h2...hM , hi : Rn −→ R, i = 1...M be so-called discriminator functions corresponding to the
class labels ω1, ω2...ωM , respectively. Then, the classifier D belonging to these discriminator functions is
defined by D( #»χ) = ωj∗ ⇔ hj ∗ ( #»χ) = max1≤j<M (hj( #»χ)) for all χ ∈ Rn
3. Let D1, D2...DL be classifiers. Then, the majority voting ensemble classifier Dmaj : Rn −→ Ω formed
from these classifiers is defined as Dmaj(
#»χ) = ωi∗ ⇔ |{j : Dj( #»χ) = ωi, j = 1...M}|.
Inputs
The inputs, represented as feature vectors, are as such:
1. χ1–FIT result: this is the result of the occult blood test. Blood in the stool is presents a high risk
of CRC.
2. χ2–BMI: a unique weight/height ratio. Higher BMIs put a patient at higher risk of CRC.
3. χ3–Age: older people are more likely to get CRC.
4. χ4–Diabetes: Presence of diabetes imposes a risk of CRC
5. χ5–Smoking: Patients who smoke are much more likely to get CRC than those who do not.
Classifiers
To select the best classifiers for classification, quite a few well-known classifiers were trained on the
dataset. Classifiers were selected using backward search methods investigated in (Ruta and Gabrys,
2005) for a fixed set of classifiers. A backward search starts out with all classifiers as part of the ensem-
ble, but as the performance of the ensemble increases, classifiers are then removed, thereby resulting in
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the optimal ensemble. The end result ensemble is composed of extreme gradient boosted trees, logistic
regression, random forests, decision trees, an artificial neural network, and a support vector machine.
Hyperparameters were adjusted to adjust for a small dataset with multiple inputs. Most notably, the
artificial neural network has an L-BFGS solver to account for a small dataset and inter-related inputs
in combination with a hyperbolic tangent activation function. The logistic regression classifier has a
liblinear solver for optimization of small datasets. The support vector machine has a linear kernel.
Metrics
Metrics were calculated as follows after ten-fold cross validation:
1. Precision: TP
TP+FP
2. Sensitivity/Recall: TP
TP+FN
3. Specificity: TN
TN+FP
4. F-Score: 2TP
2TP+FN+FP
5. AUC:
∫ −∞
∞ TPR(T )(−FPR′(T ))dT
Classifier Scores
eXtreme Gradient Boosted Trees Precision: .89
Sensitivity: .86
AUC: .95
Specificity: .91
Logistic Regression Precision: .89
Sensitivity: .86
AUC: .94
Specificity: .92
Random Forest Precision: .92
Sensitivity: .89
AUC: .93
Specificity: .91
Support Vector Machine Precision: .89
Sensitivity: .86
AUC: .95
Specificity: .92
Artificial Neural Network Precision: .90
Sensitivity: .89
AUC: .95
Specificity: .89
Majority Vote Precision: .90
Sensitivity: .89
AUC: .95
Specificity: .92
F1: .88
These results were then extrapolated onto a test set and plotted on a receiver operating characteristic
(ROC) curve. The results are below:
5
Comparison with existing methods
Method Statistics
Fecal Occult Blood Tests Specificity: .96
Sensitivity: .74
Cost: $15
Time: 5 minutes
CT Colonography Specificity: .88
Sensitivity: .84
Cost: $439
Time: 30 minutes
Stool DNA Test Specificity: .89
Sensitivity: .92
Cost: $600
Time: 2 weeks
CounteractIO Specificity: .92
Sensitivity: .89
Cost: $10
Time: 5 minutes
4 Shortcomings
This has been tested for patients in the United States and Canada. Clinical research locations include
the MD Anderson Cancer Center, the University of Michigan in Ann Arbor, the Mayo Clinic, and the
Dana Farber Cancer Institute, thereby representing people from all over the country. However, the
methodology described in this paper has not been tested outside of the United States/Canada. This is
significant because people outside of the States may show different biomarkers of CRC as a result of a
different cultural upbringing. We are working on getting a larger and more diverse sample set to further
validate our results.
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5 Conclusion
CounteractIO fills a void that has a great need in the current world of CRC detection. Current tests are
not accessible, accurate, quick, as well as noninvasive. The fact that CounteractIO is able to fit all four
of those criteria makes it highly desirable to patients in the gastroenterology and oncology fields.
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